AstraZeneca is writing a $600 million upfront check, with up to $900 million more in milestones, for exclusive worldwide rights to Dizal Pharmaceutical’s lung cancer pill Zegfrovy. Total deal value: $1.5 billion, plus tiered royalties on top, per the global exclusive license agreement the Shanghai biotech announced Tuesday.
Absent from the deal: any carve-out for Greater China, the usual clause in these cross-border pharma deals. AstraZeneca gets the whole map.
What’s it buying? Zegfrovy already cleared FDA accelerated approval in July 2025 for NSCLC patients who’d already failed chemo. That’s the small prize. The bigger one sits in Dizal’s Phase 3 WU-KONG28 data, published in the New England Journal of Medicine: a 35% cut in the risk of progression or death versus chemo, first-line, with response rates near 60% against 31% for the control arm. If frontline approvals land in the US and China, AstraZeneca isn’t just buying a post-chemo niche drug, it’s buying a shot at the much larger newly-diagnosed EGFR exon 20 market.
This isn’t a one-off. It’s AstraZeneca’s third Asian licensing deal this month, following a January obesity pact and a June kidney-disease agreement with CSPC Pharmaceutical, the latter worth up to $1.77 billion, plus a $1.9 billion respiratory deal with Sino Biopharmaceutical last week. The pharma is buying pipeline, one Chinese biotech at a time.
The transaction is expected to close later this year, once those frontline regulatory decisions start landing.
Diana Kowalski